Accelerate Diagnostics

Accelerate Diagnostics' mission is to address the critical public health crisis of antimicrobial resistance by radically accelerating the time to actionable diagnostic results. Its primary achievement is the FDA-cleared Accelerate Pheno™ system, which provides phenotypic antibiotic susceptibility testing (AST) results in about 7 hours from a positive blood culture, a significant improvement over traditional methods that take 1-3 days. The company's strategy centers on commercializing this platform in hospitals globally, demonstrating its clinical and economic value to drive adoption, and expanding its test menu to address a broader range of infections. While the technology is recognized as innovative, the company has faced commercial execution challenges in a complex and cost-sensitive healthcare market.

A proprietary morphology-based diagnostic platform utilizing automated microscopy, fluorescence in situ hybridization (FISH), and morphokinetic cellular analysis (MCA) to perform rapid identification and phenotypic antibiotic susceptibility testing (AST) directly from positive blood cultures.

Accelerate competes with slow but entrenched traditional AST systems (bioMérieux, BD, Beckman Coulter), rapid molecular ID/resistance gene detectors (BioFire, Roche/GenMark), and emerging next-gen platforms. Its key differentiation is providing rapid *phenotypic* susceptibility results (~7 hours), a unique niche between fast genotypic prediction and slow traditional phenotypic confirmation.